Nemaura Medical (NASDAQ:NMRD) versus MiMedx Group (NASDAQ:MDXG) Head to Head Contrast

Nemaura Medical (NASDAQ:NMRD) and MiMedx Group (NASDAQ:MDXG) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, earnings, risk, valuation, analyst recommendations, profitability and institutional ownership.

Risk and Volatility

Nemaura Medical has a beta of 0.63, meaning that its share price is 37% less volatile than the S&P 500. Comparatively, MiMedx Group has a beta of 1.85, meaning that its share price is 85% more volatile than the S&P 500.

Valuation & Earnings

This table compares Nemaura Medical and MiMedx Group”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nemaura Medical	$3,017.00	1.34	-$14.14 million	($0.39)	0.00
MiMedx Group	$352.38 million	2.82	$58.23 million	$0.27	24.89

MiMedx Group has higher revenue and earnings than Nemaura Medical. Nemaura Medical is trading at a lower price-to-earnings ratio than MiMedx Group, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Nemaura Medical and MiMedx Group’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Nemaura Medical	N/A	N/A	N/A
MiMedx Group	23.86%	26.21%	18.15%

Institutional and Insider Ownership

4.4% of Nemaura Medical shares are owned by institutional investors. Comparatively, 79.2% of MiMedx Group shares are owned by institutional investors. 40.4% of Nemaura Medical shares are owned by insiders. Comparatively, 1.7% of MiMedx Group shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Nemaura Medical and MiMedx Group, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nemaura Medical	0	0	0	0	0.00
MiMedx Group	0	0	2	0	3.00

MiMedx Group has a consensus target price of $12.50, indicating a potential upside of 86.01%. Given MiMedx Group’s stronger consensus rating and higher possible upside, analysts plainly believe MiMedx Group is more favorable than Nemaura Medical.

Summary

MiMedx Group beats Nemaura Medical on 13 of the 14 factors compared between the two stocks.

About Nemaura Medical

Nemaura Medical Inc., a medical technology company, manufactures continuous glucose monitoring system in the United States. It offers sugarBEAT, a non-invasive continuous glucose monitoring device for use by persons with Type I and Type II diabetes, as well as screen pre-diabetic patients. The company also offers proBEAT, a wellness guidance notes, that provide prompts and educate users on factors affecting blood sugar profiles, as well as conducts diabetes prevention and reversal programs. Nemaura Medical Inc. was founded in 2009 and is based in New York, New York.

About MiMedx Group

MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins. The company’s patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a barrier membrane allograft used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers; AmnioFix, a protective barrier allograft, which comprises dehydrated human amnion/chorion membrane for use in surgical recovery applications; and EpiCord and AmnioCord are dehydrated human umbilical cord allografts that are used to provide a protective environment for the healing process, as well as used in the advanced wound care and surgical recovery applications. The company’s products have applications in the areas of wound care, burn, surgical sectors of healthcare. The company sells its products through direct sales force and independent sales agents, as well as through independent distributors primarily in the United States. MiMedx Group, Inc. was founded in 2006 and is headquartered in Marietta, Georgia.